Shanghai RAAS (SHE: 002252), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to commence a Phase I clinical study for SR604. The drug candidate is intended as a preventive treatment for bleeding episodes in patients with hemophilia and congenital factor VII deficiency, and is designed for subcutaneous administration on a once-every-4-weeks schedule.
SR604 is a humanized monoclonal antibody (mAb) with a high affinity for human activated protein C, developed to specifically inhibit its anticoagulant function. The drug is aimed at preventing and treating bleeding in patients with hemophilia and congenital factor VII deficiency. Currently, the standard preventive treatment for hemophilia involves intravenous injections of blood or recombinant clotting factors two to three times per week, both domestically and internationally. At present, there is no similar product available on the global market.- Flcube.com
